An unconsciously new coronavirus has infected 5 million people worldwide, and there are still no signs of stopping, so it is very important to develop a new vaccine against coronavirus. The vaccine ChAdOx1 nCoV-19, developed by the University of Oxford in the United Kingdom, has previously proven itself in animal experiments but still failed, and the resulting antibodies could not neutralize the virus.
The ChAdOx1 nCoV-19 vaccine is a new coronavirus vaccine developed jointly by the NIH National Hospital of Health and the University of Oxford in the United States, previously tested on 6 rhesus monkeys. This month, they announced that monkeys successfully produce antibodies after injection of the strain. ,
However, the good news came soon after the bad news: after the monkeys were exposed to the new coronavirus, they all became infected and showed obvious symptoms.
Compared with the non-vaccinated control group, the amount of virus detected in monkey nasal secretions is the same, which means that the antibodies produced by the vaccine have no effect. This vaccine can be said to have failed, at least for the current test.
The only good news is that in which the 3 monkeys although there are shortness of breath problems, there is no obvious lung damage, Oxford research and development of this vaccine may have some protective effect, but if the new corona for the prevention of the virus were unsuccessful.
In terms of global vaccine research and development, the British Oxford vaccine is one that has been clinically verified outside of China and the United States. The failure of this vaccine means that all vaccines currently in the clinical stage are developed by Chinese or American companies.
According to previous news from the Ministry of Science and Technology, China has completed the first and second phases of clinical trials of the adenoviral vector vaccine in five current technical routes. The results of the first phase have also been preliminarily evaluated. In addition 4 Ge inactivated vaccine has also been conducting clinical trials. There are currently 10 vaccines in clinical trials worldwide, so China’s vaccine research is being promoted together with the world.
Research: Antibodies found in SARS recoveries inhibit new coronavirus
According to foreign media reports, recent studies have claimed that antibodies found during rehabilitation from SARS can inhibit the new coronavirus.
Researchers working on the treatment of new monoclonal antibodies to coronavirus have found an antibody among surviving SARS that can also neutralize SARS-CoV-2 and prevent COVID-19. The anti-SARS antibody can be used in combination drugs to prevent the attachment of new viruses to cells and enhance the immune response.
The latest study details an unusual but exciting discovery: researchers have found that SARS reducing antibody can be used to inhibit SARS-CoV-2. SARS is another coronavirus that caused 8,422 infections in the world in 2003, of which 919 were killed.
In a new study published in the journal Nature, researchers isolated an antibody called S309 from the SARS healer. The study was conducted by doctors from the University of Washington, the Pasteur Institute in France, the University of Ticino, Switzerland, and Vir Biotechnology. Vir is one of the U.S. companies that is currently seeking to develop monoclonal antibodies to COVID-19.
The S309 antibody found in the blood of this healer showed a strong ability to bind to the S protein of the new coronavirus, and the S protein is a key viral component of SARS and SARS-CoV-2, which allows these two viruses to attach On the cell and invade the cell. Without this process, the virus cannot enter the cell and replicate itself.
The researchers determined that S309 is the most effective SARS neutralizing antibody, which can block the new coronavirus, but the researchers said that it may combine with other SARS antibodies that are less active against SARS-CoV-2 to form an antibody combination drug that can provide extra protection.